SignatureFD’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

SignatureFD’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-356	Closed	-$3K	–	2749
2020 Q1	$3K	Buy	356 +351	+7,020%	+$4.38K	﹤0.01%	1885
2019 Q4	$0	Hold	5	–	–	﹤0.01%	2345
2019 Q3	$0	Hold	5	–	–	﹤0.01%	2267
2019 Q2	$0	Hold	5	–	–	﹤0.01%	2228
2019 Q1	$0	Hold	5	–	–	﹤0.01%	2101
2018 Q4	$0	Buy	+5	New	+$103	﹤0.01%	2130

Other funds holding PTLA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

SignatureFD's PTLA Position: Q2 2020 in Review

SignatureFD sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 356 shares — an estimated $3K sold.

SignatureFD first reported a position in PTLA in Q4 2018 and held it in 6 quarters. The position peaked at $3K in Q1 2020. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.

SignatureFD reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
SignatureFD sold 356 Portola Pharmaceuticals, Inc. shares in Q2 2020, an estimated $3K.
SignatureFD first reported a position in Portola Pharmaceuticals, Inc. in Q4 2018 and held it in 6 quarters.
SignatureFD's Portola Pharmaceuticals, Inc. position peaked at $3K in Q1 2020.
162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.

Based on SignatureFD's 13F filing for Q2 2020, filed 30 Jul 2020.